Compare MOMO & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOMO | ALVO |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | China | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.4M | 1.1B |
| IPO Year | 2014 | N/A |
| Metric | MOMO | ALVO |
|---|---|---|
| Price | $6.18 | $3.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 521.0K | 334.6K |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | $3.68 | $18.63 |
| P/E Ratio | ★ $10.60 | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.69 | $3.03 |
| 52 Week High | $9.22 | $11.85 |
| Indicator | MOMO | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 47.58 |
| Support Level | $5.69 | $3.03 |
| Resistance Level | $6.32 | $3.93 |
| Average True Range (ATR) | 0.17 | 0.17 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 38.39 | 34.37 |
Hello Group Inc provides mobile-based social networking services. It enables users to establish and expand social relationships based on location and interests. Its platform includes the Momo mobile application and a variety of related features, functionalities, tools, and services that it provides to users, customers, and platform partners. The company derives its revenue from live video services, value-added services, mobile marketing services, mobile games, and other services. It operates in three segments: Momo's service lines, Tantan's service lines, and QOOL's service lines, out of which Momo's service lines segment derives the majority of revenue.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.